Maze Therapeutics

press releases archive

The information in our press releases and presentations should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.

February 27, 2023
Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
December 16, 2022
Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
November 4, 2022
Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease
October 12, 2022
Maze Therapeutics Appoints Harold Bernstein, M.D., Ph.D., as President, Research and Development and Chief Medical Officer
September 22, 2022
Maze Therapeutics Appoints Sekar Kathiresan, M.D., to its Board of Directors
recent

want to get a hold of a representative?

Jillian Connell
Maze Therapeutics
jconnell@mazetx.com

media inquires

Katie Engleman
1AB
katie@1abmedia.com

Contact Us
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Essential Cookies

These cookies are necessary for our website to function and for measurement purposes. Opt-out rights do not apply to these cookies.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Powered by  GDPR Cookie Compliance